SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001104659-17-057375
Filing Date
2017-09-15
Accepted
2017-09-15 13:52:09
Documents
1
Group Members
VERSANT AFFILIATES FUND V, L.P.VERSANT OPHTHALMIC AFFILIATES FUND I, L.P.VERSANT SIDE FUND IV, L.P.VERSANT VENTURE CAPITAL V (CANADA) LPVERSANT VENTURE CAPITAL V, L.P.VERSANT VENTURES IV, LLCVERSANT VENTURES V (CANADA), L.P.VERSANT VENTURES V GP-GP (CANAD

Document Format Files

Seq Description Document Type Size
1 SC 13D/A a17-22114_1sc13da.htm SC 13D/A 370331
  Complete submission text file 0001104659-17-057375.txt   372266
Mailing Address ONE SANSOME STREET SUITE 3630 SAN FRANCISCO CA 94104
Business Address ONE SANSOME STREET SUITE 3630 SAN FRANCISCO CA 94104 650-233-2211
Versant Venture Capital IV, L.P. (Filed by) CIK: 0001456590 (see all company filings)

IRS No.: 263080195 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Subject) CIK: 0001674416 (see all company filings)

IRS No.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89674 | Film No.: 171087637
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences